ArticleFrontiers in pharmacology2025
Guanxinning attenuates diabetic myocardial ischemia-reperfusion injury by targeting oral
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reframing glucolipid metabolic disorders through the lens of the oral microbiome: from pathophysiological mechanisms to translational potential.Frontiers in nutrition · 2026Review
- Comparative efficacy and safety of oral Chinese patent medicines combined with conventional therapy for coronary heart disease complicated by diabetes: a systematic review and network meta-analysis.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence and severity of diabetic myocardial ischemia reperfusion injury (DMIRI) are increasing, highlighting the urgent need for effective prevention and treatment. Previous studies have revealed that specific oral microbiota ( Proposal: This study investigates whether GXN alleviates DMIRI by modulating Methods: The effects of GXN on cardiac injury, cardiac protein expression and the abundance of Results: GXN treatment significantly reduced myocardial injury in diabetic mice and decreased oral Conclusion: GXN may alleviate DMIRI by targeting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.